Skip to main content

Using negative control outcomes to assess the comparability of treatment groups among postmenopausal women switching osteoporosis therapy

Publication ,  Conference
McGrath, LJ; Kim, M; Pritchard, D; Yu, Y; Samai, P; Balasubramanian, A; Lin, J; Spangler, L; Stad, R; Bradbury, BD; Brookhart, MA
Published in: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
2021

Duke Scholars

Published In

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

EISSN

1099-1557

ISSN

1053-8569

Publication Date

2021

Volume

30

Start / End Page

389 / 390

Related Subject Headings

  • Pharmacology & Pharmacy
  • 4202 Epidemiology
  • 3214 Pharmacology and pharmaceutical sciences
  • 1117 Public Health and Health Services
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McGrath, L. J., Kim, M., Pritchard, D., Yu, Y., Samai, P., Balasubramanian, A., … Brookhart, M. A. (2021). Using negative control outcomes to assess the comparability of treatment groups among postmenopausal women switching osteoporosis therapy. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 30, pp. 389–390).
McGrath, Leah J., Min Kim, David Pritchard, Ying Yu, Peter Samai, Akhila Balasubramanian, Jay Lin, et al. “Using negative control outcomes to assess the comparability of treatment groups among postmenopausal women switching osteoporosis therapy.” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 30:389–90, 2021.
McGrath LJ, Kim M, Pritchard D, Yu Y, Samai P, Balasubramanian A, et al. Using negative control outcomes to assess the comparability of treatment groups among postmenopausal women switching osteoporosis therapy. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021. p. 389–90.
McGrath, Leah J., et al. “Using negative control outcomes to assess the comparability of treatment groups among postmenopausal women switching osteoporosis therapy.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 30, 2021, pp. 389–90.
McGrath LJ, Kim M, Pritchard D, Yu Y, Samai P, Balasubramanian A, Lin J, Spangler L, Stad R, Bradbury BD, Brookhart MA. Using negative control outcomes to assess the comparability of treatment groups among postmenopausal women switching osteoporosis therapy. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021. p. 389–390.

Published In

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

EISSN

1099-1557

ISSN

1053-8569

Publication Date

2021

Volume

30

Start / End Page

389 / 390

Related Subject Headings

  • Pharmacology & Pharmacy
  • 4202 Epidemiology
  • 3214 Pharmacology and pharmaceutical sciences
  • 1117 Public Health and Health Services
  • 1115 Pharmacology and Pharmaceutical Sciences